412950-08-4

412950-08-4 structure

Name: Rilapladib
Chemical Name: 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
CAS Number: 412950-08-4
Molecular Formula: C₄₀H₃₈F₅N₃O₃S
Molecular Weight: 735.80500
Catalog: Signaling Pathways Metabolic Enzyme/Protease Phosphatase
Create Date: 2018-04-17 08:00:00
Modify Date: 2024-01-20 07:11:34
Rilapladib is a selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) inhibitor with an IC50 of 230 pM.

Name	2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
Synonyms	MTdU Rilapladib UNII-O14CWE893Z

Description	Rilapladib is a selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) inhibitor with an IC50 of 230 pM.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphatase Research Areas >> Neurological Disease
Target	IC50: 230 pM (Lp-PLA2)[1].
References	[1]. Shaddinger BC, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials. PLoS One. 2014 Jan 27;9(1):e83094.

412950-86-8

412950-89-1

~82%

412950-08-4

Literature: GLAXO GROUP LIMITED; LEE, Mei-yin Patent: WO2013/30374 A1, 2013 ; Location in patent: Page/Page column 22; 23 ;